The Immune System—A Double-Edged Sword for Adenovirus-Based Therapies
Viruses · 17.06.2024 · 16 (6) · 973
DOI: 10.3390/v16060973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 17.06.2024. Verfasst von Rebecca Wallace und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK. Hauptthemen laut MEDLINE: Adenoviridae, Genetic Vectors, Genetic Therapy, Adaptive Immunity. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 316 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Cancer Research UK Biotherapeutic Programme, HEFCW.
Abstract (Originalsprache)
Pathogenic adenovirus (Ad) infections are widespread but typically mild and transient, except in the immunocompromised. As vectors for gene therapy, vaccine, and oncology applications, Ad-based platforms offer advantages, including ease of genetic manipulation, scale of production, and well-established safety profiles, making them attractive tools for therapeutic development. However, the immune system often poses a significant challenge that must be overcome for adenovirus-based therapies to be truly efficacious. Both pre-existing anti-Ad immunity in the population as well as the rapid development of an immune response against engineered adenoviral vectors can have detrimental effects on the downstream impact of an adenovirus-based therapeutic. This review focuses on the different challenges posed, including pre-existing natural immunity and anti-vector immunity induced by a therapeutic, in the context of innate and adaptive immune responses. We summarise different approaches developed with the aim of tackling these problems, as well as their outcomes and potential future applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK.
- Systems Immunity University Research Institute, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK.
ORCID-Profile: Alan L Parker
Förderung
- Cancer Research UK
- Cancer Research UK Biotherapeutic Programme
- HEFCW
Zitieren
APA
Wallace, R., Bliss, C. M., & Parker, A. L. (2024). The Immune System—A Double-Edged Sword for Adenovirus-Based Therapies. Viruses, 16(6), 973. https://doi.org/10.3390/v16060973
Vancouver
Wallace R, Bliss CM, Parker AL. The Immune System—A Double-Edged Sword for Adenovirus-Based Therapies. Viruses. 2024;16(6):973. doi:10.3390/v16060973
BibTeX
@article{Wallace2024,
author = {Wallace, Rebecca and Bliss, Carly M and Parker, Alan L},
title = {The Immune System—A Double-Edged Sword for Adenovirus-Based Therapies},
journal = {Viruses},
year = {2024},
volume = {16},
number = {6},
pages = {973},
doi = {10.3390/v16060973}
}
EUVIMED